GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » PB Ratio

Scinopharm Taiwan (TPE:1789) PB Ratio : 1.59 (As of Apr. 01, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-01), Scinopharm Taiwan's share price is NT$21.20. Scinopharm Taiwan's Book Value per Share for the quarter that ended in Dec. 2024 was NT$13.31. Hence, Scinopharm Taiwan's PB Ratio of today is 1.59.

Good Sign:

Scinopharm Taiwan Ltd stock PB Ratio (=1.65) is close to 10-year low of 1.64.

The historical rank and industry rank for Scinopharm Taiwan's PB Ratio or its related term are showing as below:

TPE:1789' s PB Ratio Range Over the Past 10 Years
Min: 1.58   Med: 2.11   Max: 4.3
Current: 1.6

During the past 13 years, Scinopharm Taiwan's highest PB Ratio was 4.30. The lowest was 1.58. And the median was 2.11.

TPE:1789's PB Ratio is ranked better than
58.72% of 940 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs TPE:1789: 1.60

During the past 12 months, Scinopharm Taiwan's average Book Value Per Share Growth Rate was 1.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 0.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 0.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Scinopharm Taiwan was 21.00% per year. The lowest was -0.50% per year. And the median was 2.15% per year.

Back to Basics: PB Ratio


Scinopharm Taiwan PB Ratio Historical Data

The historical data trend for Scinopharm Taiwan's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan PB Ratio Chart

Scinopharm Taiwan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.17 1.85 1.93 2.01 1.66

Scinopharm Taiwan Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 2.08 2.21 1.95 1.66

Competitive Comparison of Scinopharm Taiwan's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's PB Ratio distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's PB Ratio falls into.


;
;

Scinopharm Taiwan PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Scinopharm Taiwan's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=21.20/13.311
=1.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Scinopharm Taiwan  (TPE:1789) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Scinopharm Taiwan PB Ratio Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinopharm Taiwan Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines